TheraRadar
← Back
Data updated: Jun 28, 2026

MITCHELL WEDLING SUPPLY

Pharma
Pharmaceuticals

MITCHELL WEDLING SUPPLY is a pharmaceutical company with 1 FDA-approved products.

2025
Since
1
Drugs
-
Trials
6
New Drugs (2yr)
Modality:
1 Small Molecules

MITCHELL WEDLING SUPPLY's Key Drugs

MITCHELL WEDLING SUPPLY's core commercial portfolio centers on CARBON DIOXIDE, USP — its most strategically important drugs approved in the last 15 years.

CARBON DIOXIDE, USP
Respiratory
Approved 2013

MITCHELL WEDLING SUPPLY's Recent FDA Approvals

MITCHELL WEDLING SUPPLY secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide

MITCHELL WEDLING SUPPLY's Therapeutic Areas

Disease areas where MITCHELL WEDLING SUPPLY has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

MITCHELL WEDLING SUPPLY Pipeline Snapshot

Active clinical trials for MITCHELL WEDLING SUPPLY across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CARBON DIOXIDE, USP leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling